Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The bone mass benefits of antiresorbers in postmenopausal osteoporosis are limited by the rapid coupling of decreasing bone resorption with bone formation. Wnt signaling is involved in this coupling process during treatment with bisphosphonates, whereas its role during treatment with the anti-receptor activator of NF-κB ligand (RANKL) antibody denosumab is unknown. The study population includes patients participating in a placebo-controlled trial lasting 36 months: 19 women were on placebo and 24 on subcutaneous 60 mg denosumab every 6 months. All measured parameters (serum C-terminal telopeptide of type I collagen [sCTX], serum bone alkaline phosphatase [bAP], Dickkopf-1 [DKK1], and sclerostin) remained unchanged during the observation period in the placebo group. sCTX and bAP were significantly suppressed by denosumab treatment over the entire follow-up. Denosumab treatment was associated with significant (p < 0.05) increases (28% to 32%) in serum sclerostin over the entire study follow-up. Serum DKK1 significantly decreased within the first 6 months with a trend for further continuous decreases, which reached statistical significance (p < 0.05) versus placebo group from the 18th month onward. The changes in DKK1 were significantly and positively related with the changes in sCTX and bAP and negatively with hip bone mineral density (BMD) changes. The changes in sclerostin were significantly and negatively related only with those of bAP. The changes in bone turnover markers associated with denosumab treatment of postmenopausal osteoporosis is associated with significant increase in sclerostin similar to those seen after long-term treatment with bisphosphonates and significant decrease in DKK1. This latter observation might explain the continuous increase over 5 years in BMD observed during treatment of postmenopausal osteoporosis with denosumab. © 2012 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationMechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350 · cited 1×
“Sclerostin is almost exclusively expressed in osteocytes, and its expression decreases in response to mechanical loading((17)) or exposure to parathyroid hormone (PTH),((8,18,19)) and this may locally relieve endogenous Wnt inhibition and promote bone formation.”
BackgroundLi, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · cited 1×
“RANKL interacts with RANK and stimulates activation of osteoclasts, leading to augmented bone resorption.((12)) Denosumab administration in postmenopausal osteoporosis antagonizes RANKL activity, thus diminishing not only osteoclast activity as bisphosphonates but also their recruitment and maturation.”
BackgroundSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“RANKL is mainly produced by osteoblasts and acts through the receptor activator of NF-kB (RANK) found on osteoclasts and preosteoclasts.((11)) RANKL interacts with RANK and stimulates activation of osteoclasts, leading to augmented bone resorption.”
BackgroundSOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Cited by
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
“Agents targeting the β-catenin-destruction complex chronic kidney disease (CKD)-mineral and bone disorder (CKD-MBD) begins early in the course of kidney disease and is clinically detectable in stage 2 CKD.267 DKK1 antibody are involved in the pathogenesis of CKD-MBD, neutralization of DKK1 in CKD-2 mice after renal in…”
BackgroundReview of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation
James, A. W. (2013) · Scientifica · doi:10.1155/2013/684736 · Cited by 493
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Mantovani, A., Sani, E., Fassio, A., Colecchia, A., Viapiana, O., Gatti, D., Idolazzi, L., Rossini, M., Salvagno, G., Lippi, G., et al. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.001 · Cited by 68
Mechanism and treatment strategy of osteoporosis after transplantation
Song, L., Xie, X.-B., Peng, L.-K., Yu, S.-J., & Peng, Y.-T. (2015) · International Journal of Endocrinology · doi:10.1155/2015/280164 · Cited by 30
Metadata
- Authors
- Gatti, D., Viapiana, O., Fracassi, E., Idolazzi, L., Dartizio, C., Povino, M. R., Adami, S., & Rossini, M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06-12
- Volume
- 27
- Issue
- 11
- Pages
- 2259-2263
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2034609501
- Cited by
- 102
- References
- 7
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. https://app.cochat.ai/papers/10.1002/jbmr.1681
- The paper
- Gatti, D., Viapiana, O., Fracassi, E., Idolazzi, L., Dartizio, C., Povino, M. R., Adami, S., & Rossini, M. (2012). Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.1681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.